Subscribe to our Email Alerts
Menu
Home
About Us
Company Overview
Company Values
Board of Directors
Executive Management
Corporate Directory
Products
DAYBUE® (trofinetide)
Pipeline
Pipeline
NNZ-2591
Phelan-McDermid Syndrome
Angelman Syndrome
Pitt Hopkins Syndrome
Hypoxic-ischemic encephalopathy
Prader-Willi Syndrome
Compassionate Use
Science
Science Behind Neuren's Products
Trofinetide Published Studies & Presentations
Rett Syndrome
NNZ-2591Published Studies & Presentations
Phelan-McDermid Syndrome
Pitt Hopkins Syndrome
Angelman Syndrome
Investors
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
News & Media
Media
Contact
Contact Us
Email Alerts
Investors
Home
>
Investors
>
ASX Announcements
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
ASX Announcements
Filter by Year:
2026
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
May 08, 2025
DAYBUE Q1 2025 net sales US$84.6m up 11% from Q1 2024
May 07, 2025
Update - Notification of buy-back - NEU
May 06, 2025
Notification of cessation of securities - NEU
May 06, 2025
Update - Notification of buy-back - NEU
May 05, 2025
Becoming a substantial holder
May 05, 2025
Update - Notification of buy-back - NEU
May 02, 2025
Neuren appoints Daryl DeKarske to executive team
May 02, 2025
Update - Notification of buy-back - NEU
May 01, 2025
Update - Notification of buy-back - NEU
Apr 30, 2025
Update - Notification of buy-back - NEU
Previous
1
2
3
4
5
6
7
8
9
10
11
12
13
Next
